Nektar Therapeutics Revenue
Nektar Therapeutics (NKTR) reported Revenue of $10.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-14
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $10.13M, a 9.34% decline year-over-year.
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $10.86M, a 3.83% increase year-over-year.
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $21.81M, a 25.25% decline year-over-year.
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $11.79M, a 51.13% decline year-over-year.
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for fiscal 2025 was $55.23M, a 43.89% decline from fiscal 2024.
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for fiscal 2024 was $98.43M, a 9.22% increase from fiscal 2023.
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for fiscal 2023 was $90.12M, a 2.10% decline from fiscal 2022.
- Nektar Therapeutics revenue from contract with customer, excluding assessed tax for fiscal 2022 was $92.06M, a 9.67% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.13M 10-Q · filed 2026-08-14 | $20.99M 10-Q · filed 2026-08-14 | $42.80M derived: sum of 3 quarters · filed 2026-08-14 | $54.59M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $10.86M 10-Q · filed 2026-05-08 | $32.67M derived: sum of 2 quarters · filed 2026-05-08 | $44.46M derived: sum of 3 quarters · filed 2026-05-08 | $55.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $21.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $33.60M derived: sum of 2 quarters · filed 2026-03-13 | $44.77M derived: sum of 3 quarters · filed 2026-08-14 | $55.23M 10-K · filed 2026-03-13 |
| 2025-09-30 | $11.79M 10-Q · filed 2025-11-07 | $22.96M derived: sum of 2 quarters · filed 2026-08-14 | $33.42M 10-Q · filed 2025-11-07 | $62.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $11.18M 10-Q · filed 2026-08-14 | $21.64M 10-Q · filed 2026-08-14 | $50.81M derived: sum of 3 quarters · filed 2026-08-14 | $74.93M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $10.46M 10-Q · filed 2026-05-08 | $39.63M derived: sum of 2 quarters · filed 2026-05-08 | $63.76M derived: sum of 3 quarters · filed 2026-05-08 | $87.25M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $29.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $53.30M derived: sum of 2 quarters · filed 2026-03-13 | $76.79M derived: sum of 3 quarters · filed 2026-03-13 | $98.43M 10-K · filed 2026-03-13 |
| 2024-09-30 | $24.12M 10-Q · filed 2025-11-07 | $47.61M derived: sum of 2 quarters · filed 2025-11-07 | $69.25M 10-Q · filed 2025-11-07 | $93.14M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $23.49M 10-Q · filed 2025-08-08 | $45.13M 10-Q · filed 2025-08-08 | $69.01M derived: sum of 3 quarters · filed 2025-08-08 | $93.16M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $21.64M 10-Q · filed 2025-05-09 | $45.52M derived: sum of 2 quarters · filed 2025-05-09 | $69.67M derived: sum of 3 quarters · filed 2025-05-09 | $90.17M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $23.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $48.03M derived: sum of 2 quarters · filed 2025-03-14 | $68.53M derived: sum of 3 quarters · filed 2025-03-14 | $90.12M 10-K · filed 2025-03-14 |
| 2023-09-30 | $24.14M 10-Q · filed 2024-11-08 | $44.64M derived: sum of 2 quarters · filed 2024-11-08 | $66.24M 10-Q · filed 2024-11-08 | $88.26M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $20.50M 10-Q · filed 2024-08-09 | $42.09M 10-Q · filed 2024-08-09 | $64.12M derived: sum of 3 quarters · filed 2024-08-09 | $87.74M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $21.59M 10-Q · filed 2024-05-10 | $43.62M derived: sum of 2 quarters · filed 2024-05-10 | $67.24M derived: sum of 3 quarters · filed 2024-05-10 | $88.83M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $22.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $45.65M derived: sum of 2 quarters · filed 2024-03-05 | $67.23M derived: sum of 3 quarters · filed 2024-03-05 | $92.06M 10-K · filed 2024-03-05 |
| 2022-09-30 | $23.63M 10-Q · filed 2023-11-08 | $45.21M derived: sum of 2 quarters · filed 2023-11-08 | $70.03M 10-Q · filed 2023-11-08 | $95.04M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $21.59M 10-Q · filed 2023-08-09 | $46.41M 10-Q · filed 2023-08-09 | $71.42M derived: sum of 3 quarters · filed 2023-08-09 | $96.34M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $24.82M 10-Q · filed 2023-05-10 | $49.83M derived: sum of 2 quarters · filed 2023-05-10 | $74.75M derived: sum of 3 quarters · filed 2023-05-10 | $103.08M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $25.01M 10-K · filed 2022-03-01 | $49.93M derived: sum of 2 quarters · filed 2022-11-04 | $78.26M derived: sum of 3 quarters · filed 2022-11-04 | $101.91M 10-K · filed 2024-03-05 |
| 2021-09-30 | $24.92M 10-Q · filed 2022-11-04 | $53.25M derived: sum of 2 quarters · filed 2022-11-04 | $76.90M 10-Q · filed 2022-11-04 | $100.36M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $28.33M 10-Q · filed 2022-08-05 | $51.98M 10-Q · filed 2022-08-05 | $75.44M derived: sum of 3 quarters · filed 2022-08-05 | $105.47M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $23.65M 10-Q · filed 2022-05-06 | $47.11M derived: sum of 2 quarters · filed 2022-05-06 | $77.14M derived: sum of 3 quarters · filed 2022-05-06 | $125.99M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $23.46M 10-K · filed 2022-03-01 | $53.49M derived: sum of 2 quarters · filed 2022-03-01 | $102.34M derived: sum of 3 quarters · filed 2022-03-01 | $152.91M 10-K · filed 2023-02-28 |
| 2020-09-30 | $30.03M 10-K · filed 2022-03-01 | $78.88M derived: sum of 2 quarters · filed 2022-03-01 | $129.45M 10-Q · filed 2021-11-05 | $163.31M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $48.85M 10-K · filed 2022-03-01 | $99.42M 10-Q · filed 2021-08-06 | $133.28M derived: sum of 3 quarters · filed 2022-03-01 | $162.50M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $50.57M 10-K · filed 2022-03-01 | $84.44M derived: sum of 2 quarters · filed 2022-03-01 | $113.65M derived: sum of 3 quarters · filed 2022-03-01 | $136.97M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $33.86M 10-K · filed 2021-02-26 | $63.08M derived: sum of 2 quarters · filed 2021-02-26 | $86.39M derived: sum of 3 quarters · filed 2021-02-26 | $114.62M 10-K · filed 2022-03-01 |
| 2019-09-30 | $29.22M 10-K · filed 2021-02-26 | $52.53M derived: sum of 2 quarters · filed 2021-02-26 | $80.75M 10-Q · filed 2020-11-06 | $120.58M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $23.32M 10-K · filed 2021-02-26 | $51.54M 10-Q · filed 2020-08-07 | $91.36M derived: sum of 3 quarters · filed 2021-02-26 | $119.13M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $28.22M 10-K · filed 2021-02-26 | $68.05M derived: sum of 2 quarters · filed 2021-02-26 | $95.81M derived: sum of 3 quarters · filed 2021-02-26 | $1.18B derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $39.83M 10-K · filed 2020-02-28 | $67.59M derived: sum of 2 quarters · filed 2020-02-28 | $1.16B derived: sum of 3 quarters · filed 2020-02-28 | $1.19B 10-K · filed 2021-02-26 |
| 2018-09-30 | $27.76M 10-K · filed 2020-02-28 | $1.12B derived: sum of 2 quarters · filed 2020-02-28 | $1.15B 10-Q · filed 2019-11-07 | $1.25B derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $1.09B 10-K · filed 2020-02-28 | $1.13B 10-Q · filed 2019-08-09 | $1.22B derived: sum of 3 quarters · filed 2020-02-28 | $1.37B derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $38.02M 10-K · filed 2020-02-28 | $133.48M derived: sum of 2 quarters · filed 2020-02-28 | $286.41M derived: sum of 3 quarters · filed 2020-02-28 | $321.00M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $95.47M 10-K · filed 2019-03-01 | $248.39M derived: sum of 2 quarters · filed 2019-03-01 | $282.98M derived: sum of 3 quarters · filed 2019-03-01 | $307.71M 10-K · filed 2020-02-28 |
| 2017-09-30 | $152.93M 10-K · filed 2019-03-01 | $187.52M derived: sum of 2 quarters · filed 2019-03-01 | $212.25M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $34.59M 10-K · filed 2019-03-01 | $59.32M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $24.73M 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $165.44M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |